logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Acorda’s Attempted Rally. See Also: Amgen, Merck and AstraZeneca

Acorda (ACOR)  stock was up around 10% reaching over $28 in premarket trading. The stock is trading now around $27 with its gains oscillating between $2 – $2.20. The enthusiasm for ACOR seems to be about rumors that  Biogen (BIIB)...

Read More

January 19, 2018

0

CAR-T Great News and About the Biotech Sector in General

It is obvious that the CAR-T approach to cancer treatment is here to stay and to change the way cancer has been managed for decades. Attempts to improve the novel elegant procedure safety profile and efficacy on solid cancers are...

Read More

June 1, 2017

0

Amgen’s Migraine Drug Passes the Trial Tests with High Grades

Amgen (AMGN) :  Phase 3b results from LIBERTY study assessing the safety and efficacy of  Aimovig™ (erenumab) 140 mg in patients with an episodic migraine who had experienced two to four previous preventive treatment failures demonstrate that the study  met...

Read More

January 23, 2018

0

News from Incyte and Gossip About Medivation

Incyte (INCY)   and  Eli Lilly (LLY):   Th e  New England Journal of Medicine published detailed results of RA-BEACON — a pivotal phase 3 global study of  baricitinib , a once-daily oral treatment for moderate-to-severe rheumatoid arthritis (RA). The...

Read More

March 31, 2016

0

FDA Breakthrough Therapy Designation for Alnylam's RNAi Drug Givosiran

Alnylam Pharmaceutical (ALNY) calls RNAi (RNA interference) a revolution in biology. The FDA’s just granted the firm’s RNAi therapy breakthrough for a disease nobody has ever dreamed of conquering confirms this reality in spite of spending years of efforts and...

Read More

June 2, 2017

0

ChemoCentryx’s Pancreatic Cancer Product News and Other Important Facts

ChemoCentryx (CCXI)  develops new drugs for inflammatory, autoimmune diseases and cancers. The firm’s approach comprises targeting the chemokine and chemoattractant systems with the aim of discovering, developing and commercializing orally-administered therapies for inflammation and malignancy and maybe other disease conditions. In...

Read More

January 26, 2018

0

Data From ASCO and Data from the Internet

As we wrote in Prohost Letter #409, a transformation in this year’s American Society of Clinical Oncology meeting (ASCO) is further elaborating on Checkpoint inhibition and chimeric antigen receptor T-cell (CAR-T) approaches’ limitations. Both are attempts towards making Immunotherapy for cancer...

Read More

June 6, 2017

0

The FDA Says Yes to Acadia Drug Nuplazid and More

The U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) voted 12 to 2 that the benefits outweigh the risks of Acadia’s (ACAD) drug  Nuplazid™  (pimavanserin) for the treatment of psychosis associated with Parkinson’s disease. The Prescription Drug...

Read More

March 30, 2016

0

Portola Is Still a Favorite

It is an ingenuous decision made by investors who rushed to consider betrixaban Phase 3 APEX study a failure. Betrixaban is a once-daily orally administered Factor Xa inhibitor anticoagulant.  The Phase 3 AREX study was evaluating the superiority of oral betrixaban’s extended-duration anticoagulation vs....

Read More

March 24, 2016

0

Vertex: Next-Generation Correctors VX-659 and VX-445 for Triple Combinations Promise Significant Clinical Benefits for Around 90% of People with Cystic Fibrosis.

Vertex (VRTX)  announced the selection of two next-generation correctors,  VX-659  and  VX-445 , to advance into Phase 3 development as part of two different triple combination regimens for people with cystic fibrosis (CF). The decision was based on data from...

Read More

February 1, 2018

0

  • Previous
  • 1
  • 2
  • ...
  • 26
  • 27
  • 28
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy